We have developed and validated a sensitive assay based on Western blotting coupled with chemiluminescent detection using human recombinant TPPP and CSF for the quantification of TPPP in the case of different MS patients and controls [63] (Figure 2). This evidence concerns the gene TPPP and myeloid sarcoma.